Clinical features of autoimmune pulmonary alveolar proteinosis from a large international patient cohort: baseline data from the IMPALA trial

B. Trapnell (Cincinnati, United States of America), C. Ganslandt (Austin, United States of America), I. Tarnow (Austin, United States of America), T. Jouhikainen (Austin, United States of America), G. Waterer (Perth, Australia), C. Morgan (London, United Kingdom)

Source: International Congress 2019 – Rare and ultra-rare diseases and the lungs: updates and new perspectives
Session: Rare and ultra-rare diseases and the lungs: updates and new perspectives
Session type: Oral Presentation
Number: 5328
Disease area: Airway diseases, Interstitial lung diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
B. Trapnell (Cincinnati, United States of America), C. Ganslandt (Austin, United States of America), I. Tarnow (Austin, United States of America), T. Jouhikainen (Austin, United States of America), G. Waterer (Perth, Australia), C. Morgan (London, United Kingdom). Clinical features of autoimmune pulmonary alveolar proteinosis from a large international patient cohort: baseline data from the IMPALA trial. 5328

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: